KalVista Pharmaceuticals, Inc. (KALV) Dividend History

KalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, oral protease inhibitors for the treatment of hereditary angioedema (HAE) and other medical conditions. Founded in 2009 and based in the United States, the company aims to advance targeted therapies to improve patient outcomes through innovative drug development and clinical programs.

55 Cambridge Parkway, Cambridge, MA, 02142
Phone: (857) 999-0075

Dividend History

KalVista Pharmaceuticals, Inc. currently does not pay dividends

Company News

  • Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

    The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.

    GlobeNewswire Inc.
    Featured Companies: ATXS CAMP IONS NTLA
  • Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for CrowdStrike Holdings, Inc. (NASDAQ: CRWD) from $318 to $375. Keybanc analyst Eric Heath maintained an Overweight rating. CrowdStrike shares rose 0.4% to close at $322.44 on Tuesday. See how other analysts view this stock. Piper Sandler boosted Shopify Inc. (NYSE: SHOP) price target from $56 to $63. Piper Sandler analyst Clarke Jeffries maintained an Underweight rating. Shopify shares fell 13.4% to close at $77.18 on Tuesday. See how other analysts view this stock. Needham boosted the price target for SS&C Technologies Holdings, Inc. (NASDAQ: SSNC) from $62 to $70. Needham analyst Mayank Tandon maintained a Buy rating. SS&C Technologies shares fell 1.8% to close at $60.15 on Tuesday. See how other analysts view this stock. JP Morgan raised Bruker Corporation ...

    Benzinga
    Featured Companies: BIIB BRKR C CRWD DENN HPQ MDB SHOP SSNC
  • Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?

    Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.

    Zacks Investment Research
    Featured Companies: AMRX
  • KalVista's Sebetralstat: A Pill Worth Swallowing In HAE

    KalVista is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralsta. Read why I recommend a speculative Buy for KALV stock.

    Seeking Alpha
  • Is BioCryst a Good Stock to Buy Now?

    This commercial-stage drugmaker trades for less than many of its clinical-stage peers.

    The Motley Fool
    Featured Companies: BCRX
Page data last updated 07/23/2025 16:15:23 UTC